Skip to main content
Evidence Snapshot

Thromboxane A2 receptor

CHEMBL2069 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:29Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2069
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Thromboxane A2 receptor as ChEMBL target CHEMBL2069, mapped to UniProt P21731. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Thromboxane A2 receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2069
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P21731
Thromboxane A2 receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Thromboxane A2 receptor matters

As of 2026-09-13

Thromboxane A2 receptor is reviewed as Thromboxane A2 receptor (UniProt P21731); Thromboxane A2 receptor shows approved-linked disease relevance led by Airway obstruction. 4 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 8 approved drugs, 3516 compounds, and 307 assays, with lead potency reaching pChEMBL 10.8.

Disease context
Airway obstruction

Thromboxane A2 receptor shows approved-linked disease relevance led by Airway obstruction. 4 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 4 additional disease programs remain visible in the same card. Linked drugs include SERATRODAST.

Start review with Airway obstruction because it currently carries approved-linked support. Linked drugs include SERATRODAST. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 8 approved drugs, 3516 compounds, and 307 assays for this target. The dominant activity type is IC50. CHEMBL3354618 is the current potency anchor at pChEMBL 10.8.

Use CHEMBL3354618 as the tractability anchor when discussing potency (pChEMBL 10.8).

Activity source · ChEMBL 36 via Core Engine
8 approved pChEMBL 10.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Thromboxane A2 receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P21731, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Airway obstruction is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3516
Total Compounds
307
Total Assays
8
Approved Drugs
IC50: 769.0, KI: 531.0, EC50: 141.0, KD: 255.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3354618
 10.8 IC50 —
No preferred name
CHEMBL31146
 10.3 Kd —
No preferred name
CHEMBL3354616
 10.3 IC50 —
No preferred name
CHEMBL31765
 10.0 Kd —
No preferred name
CHEMBL435382
 9.9 IC50 —

Approved Drugs

Structure Compound First Approval
RAMATROBAN
CHEMBL361812
 2000
SERATRODAST
CHEMBL70972
 1995
LAROPIPRANT
CHEMBL426559
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:29Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2069